利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.021 秒)

    Tumor vascular marker-targeted vaccines
    3.
    发明授权
    Tumor vascular marker-targeted vaccines 有权
    肿瘤血管标志物靶向疫苗

    公开(公告)号：US09290556B2

    公开(公告)日：2016-03-22

    申请号：US13121638

    申请日：2009-09-29

    申请人： George Coukos ,  Andrea Facciabene

    发明人： George Coukos ,  Andrea Facciabene

    IPC分类号： C07H21/04 ,  A61K48/00 ,  C07K14/47 ,  A61K39/00 ,  A61K51/10 ,  C07K16/28

    CPC分类号： A61K39/0011 ,  A61K41/0057 ,  A61K48/00 ,  A61K51/1045 ,  A61K2039/53 ,  A61K2039/55516 ,  A61K2039/58 ,  A61K2039/62 ,  C07H21/04 ,  C07K14/4748 ,  C07K16/2851 ,  C07K2317/24 ,  C07K2319/55

    摘要： The present invention provides methods of immunizing a subject against a tumor, inhibiting tumor growth, inhibiting tumor recurrence, treating, suppressing the growth of, or decreasing the incidence of a tumor, overcoming tolerance to a tumor vasculature marker (TVM) in a subject comprising the step of administering a vaccine comprising a TVM or a nucleic acid encoding a TVM and related vaccines. The present invention also provides a method of targeting a tumor vasculature in a subject having a tumor comprising the step of contacting said subject with a labeled compound that binds a) a tumor vasculature marker (TVM) or b) a nucleic acid molecule encoding said TVM.

    摘要翻译： 本发明提供了免疫受试者抵抗肿瘤，抑制肿瘤生长，抑制肿瘤复发，治疗，抑制肿瘤生长或降低肿瘤发生率的方法，克服了受试者中对肿瘤脉管系统标志物（TVM）的耐受性的方法，包括 施用包含TVM的疫苗或编码TVM的核酸和相关疫苗的步骤。 本发明还提供了靶向具有肿瘤的受试者的肿瘤脉管系统的方法，所述方法包括使所述受试者与结合a）肿瘤血管标志物（TVM）的标记化合物或b）编码所述TVM的核酸分子 。

    TUMOR VASCULAR MARKER-TARGETED VACCINES
    5.
    发明申请
    TUMOR VASCULAR MARKER-TARGETED VACCINES 有权
    肿瘤血管标记疫苗

    公开(公告)号：US20120035529A1

    公开(公告)日：2012-02-09

    申请号：US13121638

    申请日：2009-09-29

    申请人： George Coukos ,  Andrea Facciabene

    发明人： George Coukos ,  Andrea Facciabene

    IPC分类号： A61M5/00 ,  A61P35/00 ,  A61K51/10 ,  A61P37/04 ,  A61K39/00 ,  A61K39/395

    CPC分类号： A61K39/0011 ,  A61K41/0057 ,  A61K48/00 ,  A61K51/1045 ,  A61K2039/53 ,  A61K2039/55516 ,  A61K2039/58 ,  A61K2039/62 ,  C07H21/04 ,  C07K14/4748 ,  C07K16/2851 ,  C07K2317/24 ,  C07K2319/55

    摘要： The present invention provides methods of immunizing a subject against a tumor, inhibiting tumor growth, inhibiting tumor recurrence, treating, suppressing the growth of, or decreasing the incidence of a tumor, overcoming tolerance to a tumor vasculature marker (TVM) in a subject comprising the step of administering a vaccine comprising a TVM or a nucleic acid encoding a TVM and related vaccines. The present invention also provides a method of targeting a tumor vasculature in a subject having a tumor comprising the step of contacting said subject with a labeled compound that binds a) a tumor vasculature marker (TVM) or b) a nucleic acid molecule encoding said TVM.

    摘要翻译： 本发明提供了免疫受试者抵抗肿瘤，抑制肿瘤生长，抑制肿瘤复发，治疗，抑制肿瘤生长或降低肿瘤发生率的方法，克服了受试者中对肿瘤脉管系统标志物（TVM）的耐受性的方法，包括 施用包含TVM的疫苗或编码TVM的核酸和相关疫苗的步骤。 本发明还提供了靶向具有肿瘤的受试者的肿瘤脉管系统的方法，所述方法包括使所述受试者与结合a）肿瘤血管标志物（TVM）的标记化合物或b）编码所述TVM的核酸分子 。

    Carcinoembryonic antigen fusions and uses thereof
    6.
    发明授权
    Carcinoembryonic antigen fusions and uses thereof 有权
    癌胚抗原融合物及其用途

    公开(公告)号：US08188244B2

    公开(公告)日：2012-05-29

    申请号：US10589180

    申请日：2005-02-03

    申请人： Nicola La Monica ,  Andrea Facciabene ,  Luigi Aurisicchio ,  Gennaro Ciliberto

    发明人： Nicola La Monica ,  Andrea Facciabene ,  Luigi Aurisicchio ,  Gennaro Ciliberto

    IPC分类号： C12N15/11 ,  C12N15/63

    CPC分类号： C07K14/70503 ,  A61K2039/53 ,  C07K2319/30 ,  C07K2319/55 ,  Y02A50/472

    摘要： Polynucleotides encoding carcinoembryonic antigen (CEA) fusion proteins are provided, the CEA fusion proteins comprising a CEA protein, or functional variant thereof, fused to a substantial portion of an immunoenhancing element. The polynucleotides of the present invention can elicit an immune response in a mammal, which, in preferred embodiments, is stronger than the immune response elicited by a wild-type CEA. The gene encoding CEA is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the CEA tumor-associated antigen, wherein aberrant CEA expression is associated with a carcinoma or its development. This invention specifically provides adenoviral vector and plasmid constructs carrying polynucleotides encoding CEA fusion proteins and discloses their use in vaccines and pharmaceutical compositions for preventing and treating cancer.

    摘要翻译： 提供了编码癌胚抗原（CEA）融合蛋白的多核苷酸，包含CEA蛋白或其功能变体的CEA融合蛋白与免疫增强元件的大部分融合。 本发明的多核苷酸可以在哺乳动物中引发免疫应答，在优选的实施方案中，它们比由野生型CEA引起的免疫应答更强。 编码CEA的基因通常与人类癌的发展有关。 本发明提供了引发或增强由CEA肿瘤相关抗原表达的蛋白质产物的免疫的组合物和方法，其中异常CEA表达与癌症或其发展相关。 本发明具体提供携带编码CEA融合蛋白的多核苷酸的腺病毒载体和质粒构建体，并公开了其用于预防和治疗癌症的疫苗和药物组合物中。

    Carcinoembryonic Antigen Fusions and Uses Thereof
    7.
    发明申请
    Carcinoembryonic Antigen Fusions and Uses Thereof 有权
    癌胚抗原融合及其用途

    公开(公告)号：US20080311137A1

    公开(公告)日：2008-12-18

    申请号：US10589180

    申请日：2005-02-03

    申请人： Nicola La Monica ,  Andrea Facciabene ,  Luigi Aurisicchio ,  Gennaro Ciliberto

    发明人： Nicola La Monica ,  Andrea Facciabene ,  Luigi Aurisicchio ,  Gennaro Ciliberto

    IPC分类号： A61K39/00 ,  C07H21/04 ,  C12N15/63 ,  C12N5/06 ,  A61P35/00 ,  C12P21/02 ,  C07K19/00

    CPC分类号： C07K14/70503 ,  A61K2039/53 ,  C07K2319/30 ,  C07K2319/55 ,  Y02A50/472

    摘要： Polynucleotides encoding carcinoembryonic antigen (CEA) fusion proteins are provided, the CEA fusion proteins comprising a CEA protein, or functional variant thereof, fused to a substantial portion of an immunoenhancing element. The polynucleotides of the present invention can elicit an immune response in a mammal, which, in preferred embodiments, is stronger than the immune response elicited by a wild-type CEA. The gene encoding CEA is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the CEA tumor-associated antigen, wherein aberrant CEA expression is associated with a carcinoma or its development. This invention specifically provides adenoviral vector and plasmid constructs carrying polynucleotides encoding CEA fusion proteins and discloses their use in vaccines and pharmaceutical compositions for preventing and treating cancer.

    摘要翻译： 提供了编码癌胚抗原（CEA）融合蛋白的多核苷酸，包含CEA蛋白或其功能变体的CEA融合蛋白与免疫增强元件的大部分融合。 本发明的多核苷酸可以在哺乳动物中引发免疫应答，在优选的实施方案中，它们比由野生型CEA引起的免疫应答更强。 编码CEA的基因通常与人类癌的发展有关。 本发明提供了引发或增强由CEA肿瘤相关抗原表达的蛋白质产物的免疫的组合物和方法，其中异常CEA表达与癌症或其发展相关。 本发明具体提供携带编码CEA融合蛋白的多核苷酸的腺病毒载体和质粒构建体，并公开了其用于预防和治疗癌症的疫苗和药物组合物中。